Back to today’s briefing

Story perspectives

Breakthrough Study Shows Low-Dose ATG Preserves Beta Cell Function

9/24/2025

31 2 Full Breakdown

Summary

Story summary

At the 2025 EASD Meeting, low-dose anti-thymocyte globulin (ATG) preserves beta cell function with fewer side effects.
The phase 2 MELD-ATG study enrolled 114 participants aged 5–25, showing improved C-peptide and lower HbA1c at 0.5 mg/kg.
Good Hope Hospital's pediatric diabetes team achieved the best national audit HbA1c results, with 90% uptake of hybrid closed-loop pumps and a patient-centered approach.

1 of 1

Story summary

At the 2025 EASD Meeting, low-dose anti-thymocyte globulin (ATG) preserves beta cell function with fewer side effects.
The phase 2 MELD-ATG study enrolled 114 participants aged 5–25, showing improved C-peptide and lower HbA1c at 0.5 mg/kg.
Good Hope Hospital's pediatric diabetes team achieved the best national audit HbA1c results, with 90% uptake of hybrid closed-loop pumps and a patient-centered approach.